X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

EIGR

Closed

Eiger Biopharmaceuticals Inc

2.2725
+2.2725 (0%)
Last Update: 10 May 2024 16:30:00
Yesterday: 0.
Day's Range: 2.27 - 2.2725
Send
When Written:
 
0.8969
Eiger Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and ultra-rare diseases. The company's pipeline includes treatments for hepatitis delta virus (HDV), pulmonary arterial hypertension (PAH), lymphedema, and COVID-19. Eiger's lead product candidate, lonafarnib, is being developed as a potential treatment for HDV, a severe form of viral hepatitis that affects approximately 15 million people worldwide. The company is also developing avexitide for the treatment of post-bariatric hypoglycemia, ubenimex for lymphedema, and Zokinvy for PAH. Eiger is headquartered in Palo Alto, California, and was founded in 2008.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X